Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Biochim Biophys Acta. Author manuscript; available in PMC 2017 May 1.
Published in final edited form as:
PMCID: PMC4821723

Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology


Age-related dementia is increasingly recognized as having a mixed pathology, with contributions from both cerebrovascular factors and pathogenic factors associated with Alzheimer’s disease (AD). Furthermore, there is accumulating evidence that vascular risk factors in midlife, e.g., obesity, diabetes, and hypertension, increase the risk of developing late-life dementia. Since obesity and changes in body weight/adiposity often drive diabetes and hypertension, understanding the relationship between adiposity and age-related dementia may reveal common underlying mechanisms. Here we offer a brief appraisal of how changes in body weight and adiposity are related to both AD and dementia on vascular basis, and examine the involvement of two key adipocyte-derived hormones: leptin and adiponectin. The evidence suggests that in midlife increased body weight/adiposity and subsequent changes in adipocyte-derived hormones may increase the long-term susceptibility to dementia. On the other hand, later in life, decreases in body weight/adiposity and related hormonal changes are early manifestations of disease that precede the onset of dementia and may promote AD and vascular pathology. Understanding the contribution of adiposity to age-related dementia may help identify the underlying pathological mechanisms common to both vascular dementia and AD, and provide new putative targets for early diagnosis and therapy.


Age-related dementia is an incurable condition characterized by progressive cognitive decline in the elderly. This devastating disease affects an estimated 35.6 million people worldwide and is expected to become a major health epidemic if no effective therapy is developed [1]. The underlying etiology is complex and multi-factorial, but Alzheimer’s disease (AD) and cognitive impairment on vascular bases (vascular cognitive impairment and dementia) constitute the vast majority of the age-related dementias. Alzheimer’s disease is a progressive neurodegenerative disorder that is defined by the neuropathological hallmarks of amyloid plaques and neurofibrillary tangles comprised of abnormal accumulation of amyloid-beta (Aβ) peptides and hyperphosphorylated tau, respectively [2]. On the other hand, vascular dementia is a heterogeneous group of brain disorders where cognitive decline is attributable to a wide range of cerebrovascular pathologies [3].

In the past, AD and vascular dementia were considered distinct disorders; however, accumulating evidence suggests that there is significant overlap between these two conditions [4]. Dementia due to vascular causes is likely to represent one end of a spectrum of age-related dementia, while dementia due to AD pathology may represent another end of the spectrum, with many cases having contributions from both [46]. Epidemiological studies have supported this notion by demonstrating that traditional vascular risk factors such as obesity, hypertension, and diabetes can all increase the risk of age-related cognitive decline and dementia [79]. Since disorders in body weight, obesity in particular, can increase the risk for cardiovascular disease [10] and often drive the hypertension and insulin resistance [11,12], factors that modulate body weight and adiposity may be significant contributors to age-related dementia caused by either vascular or AD pathology. In addition, dysfunction of the hypothalamus, a region of the brain that is critical for the central regulation of body weight and systemic metabolism, are commonly seen in AD and related dementias [13]. Therefore, understanding the mechanisms through which changes in body weight and adiposity contribute to impaired cognition may enable us to identify common pathways for age-related dementia.

Here, we review the evidence supporting the notion that alterations in body weight, adiposity in particular, can influence the risk of developing age-related dementia through both vascular factors and pathological mechanisms associated with AD. We first examine the epidemiological evidence linking changes in body weight and adiposity to age-related dementia and brain pathologies. We then focus on two adipocyte-derived hormones, leptin and adiponectin, as examples for how factors that regulate and are regulated by adiposity can interact with the brain resulting in neurovascular changes, worsening AD pathology, and eventually cognitive decline and dementia.

Vascular dementia and Alzheimer’s disease: age-related dementia as a spectrum

During the early 1900s Alois Alzheimer first identified dementia associated with plaques and tangles as a distinct pathological condition that was different from common forms of cognitive decline, at the time attributed to cerebrovascular pathology (“hardening of the arteries”) [3]. However, in the 1990s, the molecular identification of Aβ peptides as the major component of the plaques and the subsequent identification of mutations in the amyloid precursor protein (APP) in familial forms of AD rapidly shifted the focus from cerebrovascular causes of dementia to those caused by AD pathology. A dichotomous framework was thus developed over time where age-related dementia was defined as vascular dementia when the cognitive decline was attributable to cerebrovascular causes and AD when the cognitive decline was attributable to amyloid and tau pathology. While AD has received the bulk of attention in regards to drug discovery efforts for age-related dementia [14], it has become increasingly recognized that many patients have a mixed pathological picture with contributions from both vascular and AD pathologies [46]. This is not surprising since both cerebrovascular disease and AD pathology significantly increase in prevalence with aging. Furthermore, epidemiological studies have increasingly demonstrated that traditional vascular risk factors, such as obesity, diabetes and hypertension, have important etiological roles not only in vascular dementia but also in AD [79]. Due to the increased recognition of a significant overlap between these conditions, there is a need to examine vascular dementia and AD beyond a simple dichotomy, but as part of a continuous spectrum of age-related dementia where factors contributing to either vascular dementia or AD are considered together [15].

Since obesity, hypertension, and diabetes are now believed to be involved in the pathogenesis of age-related dementia, there is an urgent need to explore how these risk factors relate to the dementia on a mechanistic level. Here, we will focus on obesity and body weight disorders because changes in adiposity can often drive the pathological mechanisms underlying both hypertension and diabetes [11,12]. While there may be overlap among adiposity, hypertension, diabetes and their contributions to age-related dementia, adiposity has been found to be an independent risk factor for age-related dementia [7], suggesting that there are also potentially independent contributing factors related to adiposity. Therefore, understanding how adiposity affects brain structure and function could help identify common molecular and cellular mechanisms underlying both vascular and AD pathologies in age-related dementia.

Body weight/adiposity in normal aging and age-related dementia

In normal healthy adults, the body composition changes with aging. Thus, adiposity generally increases throughout midlife until late-life around the seventh or eighth decade of life [16,17]. The increase in adiposity is most evident in visceral adipose tissue, while there may be decreases in subcutaneous adipose tissue. Once late-life is reached, body weight tends to decrease as part of normal aging, which results from a combination of loss of lean tissue mass or sacropenia and loss of adipose mass. This age-associated change in body composition, where adiposity increases throughout midlife but decreases once late-life is reached, has been consistently found in several different ethnic groups and may be influenced by dietary intake [1820]. Furthermore, an epidemiological study investigating the influence of the recent obesity epidemic on the age-related changes in body composition found that later birth cohorts had higher percent body fat compared to earlier birth cohorts in both men and women, but the overall pattern of initially increasing percent body fat with age then a leveling off later in life was the same amongst the different birth cohorts [21]. These studies strongly suggest that there are fundamental mechanisms that regulate changes in body composition with aging, which, however, remain unclear. One possibility is that the age-related changes in body composition may be due to changes in the homeostatic response to hormonal and signaling factors that regulate body weight and adiposity [22]. Additionally, other factors such as changes in circadian rhythm, which are commonly seen with aging and aging-related dementia, may impact systemic metabolism that lead to age-related alterations in body weight and body composition [23,24].

Several epidemiological studies have consistently demonstrated that midlife obesity is a risk factor for developing cognitive decline and dementia that is independent of other known vascular risk factors, such as hypertension and diabetes [7,2527]. Similarly, diets high in saturated fatty acids, a major cause of obesity, have been associated with increased risk of developing AD and exacerbation of AD pathology in several animal and human studies [2830]. This positive association between body weight and dementia has been consistently reported in several different countries and ethnic groups [7,2527,3133]. However, a recent epidemiological study from the UK found that midlife obesity reduced the risk of developing dementia [34]. Although the reasons for this discrepancy are not clear, one contributing factor could be that using body weight or body mass index (BMI) as a measure of body composition and adiposity does not distinguish between changes that are due to alterations in lean mass from adipose mass. Future studies using more accurate measurements of body composition (e.g., imaging adipose tissue using computed tomography or similar imaging modalities) may provide a more coherent view of the relationship between adiposity and dementia [35]. These potential methodological confounders aside, the majority of studies thus far support a link between midlife obesity and dementia (see Table for summary of studies).

Select epidemiological studies investigating the association between midlife body weight (BMI) and incident dementia

Late-life body weight changes are also commonly seen once the dementia manifests. Weight loss was originally listed in the 1984 report by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) work group as one of the clinical features consistent with a diagnosis of probable AD [36]. Importantly, the weight loss in AD and related dementias correlates with disease morbidity and mortality since individuals who lose body weight have more rapid disease progression and increased risk of death [37,38]. In addition, several population studies have consistently demonstrated that low body weight in late-life is associated with an increased risk of developing cognitive decline and dementia [3945]. The appreciation that AD pathology develops decades prior to the initial cognitive symptoms suggest that the late-life changes in body weight may reflect the earliest stage of the disease process [40,46]. Supporting this notion, low BMI is associated with worsening AD pathology in postmortem brains [47,48] as well as worsening CSF biomarkers (tau and Aβ1–42) [49]. Collectively, these studies suggest that increased adiposity during midlife contribute or influence the risk of developing age-related dementia, while reduced adiposity in late-life is an early consequence of the disease and may contribute to its progression. The underlying mechanisms for the weight changes in AD have not been elucidated. Interestingly, alterations in feeding behavior secondary to reduced mental capacity may not play a role since the weight loss often precedes the cognitive decline [40,44]. Another hypothesis is that AD pathology involving hypothalamic centers regulating body weight homeostasis leads to uncoupling between food intake and energy expenditure, as seen in mouse models of AD [50]. However, while there is accumulating evidence of hypothalamic dysfunction in AD [51] further studies are needed to provide insight into the impact of AD pathology on central mechanisms regulating body weight homeostasis.

Adipose tissue as an endocrine organ

The white adipose tissue (WAT) was classically believed to be simply a fat storage depot tissue. However, the identification of the adipocyte hormone leptin has revolutionized the field to now view the adipose tissue as a major endocrine organ releasing hundreds of peptides, proteins, metabolites and inflammatory signals to modulate a wide variety of physiological functions [52,53]. WAT is dynamic and changes in adiposity will change the amount and nature of the factors that are secreted from it [53]. While an exhaustive appraisal of all the signaling molecules produced and regulated by WAT is beyond the scope of this review, we will focus on leptin and adiponectin as examples of adipocyte derived factors that affect vascular and AD pathology in age-related dementia.

Leptin: adiposity and systemic metabolism

Leptin is a 16kDa adipocyte-derived hormone that is secreted in proportion to the adipose stores with high circulating plasma levels in obesity and low circulating plasma levels in states of starvation [5456]. This positive correlation between body adiposity and circulating leptin levels persists throughout aging and in older adults [20,57,58]. Leptin has both central and peripheral actions by binding to its receptors, which are part of the class I cytokine family, and activating several key downstream intracellular signaling pathways [59]. The hypothalamus is a major site of action of leptin in the brain, where leptin acts as a negative feedback signal in the afferent loop that maintains body weight homeostasis by regulating feeding behavior, energy expenditure, thermogenesis, autonomic function, and systemic metabolism including insulin sensitivity and facilitating lipolysis [54]. Therefore, high plasma leptin due to increased adiposity would reflect a state of energy excess and activate the hypothalamic circuit to lower adipose mass by coordinating a complex physiological response including decreasing food intake, increasing energy expenditure, and increasing sympathetic tone [54]. Leptin can also act by central and peripheral mechanisms to improve glucose metabolism by increasing insulin sensitivity and by insulin-independent mechanisms [60,61]. Recently, leptin has been demonstrated to mediate the increase in blood pressure associated with obesity through hypothalamic circuits [62]; however, whether leptin can directly modulate blood pressure in humans remains controversial [63]. In addition to its metabolic effects, leptin has also been demonstrated to have pleotropic effects including immune regulation, reproduction, and bone metabolism [64].

Rare autosomal recessive mutations in the leptin gene result in morbid obesity associated with hyperphagia and severe neuroendocrine abnormalities that are corrected with exogenous leptin replacement therapy [65]. However, most forms of obesity are not from a lack of leptin but are associated with high circulating leptin due to the increased adiposity, resulting ultimately in leptin resistance [66]. Therefore, it is not surprising that exogenous leptin administration has little effect in obesity associated with high plasma leptin [67,68]. Despite the initial disappointment in the lack of efficacy of leptin in common obesity, leptin treatment using a recombinant modified form of leptin (metreleptin) was recently approved by the US Federal Drug Agency for the treatment of congenital or acquired generalized lipodystrophy and appears to be a promising therapy for other disorders associated with leptin deficiency or low circulating leptin [68].

Leptin: cerebrovascular disease and dementia

Leptin has a strong neuroprotective effect under a variety of pathologies in experimental models. In particular, leptin treatment ameliorates ischemic damage in models of oxygen-glucose deprivation in vitro and in animal models of focal cerebral ischemia produced by occlusion of the middle cerebral artery [69,70]. Furthermore, exogenous leptin can augment the cerebral hemodynamic reserve in a three-vessel occlusion cerebral ischemic model [71]. Conversely, larger infarct volume after focal cerebral ischemia is seen in leptin deficient ob/ob mice when compared to wild-type mice [72]. The beneficial effects of leptin is mediated in part through JAK-STAT3 signaling pathways that lead to the induction of the anti-apoptotic protein Bcl-xL, stabilization of mitochondrial membrane potential, and reduction in mitochondrial oxidative stress [73]. Despite the strong evidence for leptin having a protective effect against cerebral ischemia in preclinical studies, several epidemiological studies have found that high circulating leptin levels are associated with ischemic cerebrovascular disease [7476]. While a pathogenic role of high circulating leptin cannot be entirely excluded, the association with ischemic stroke seen in these studies is likely to reflect leptin resistance leading to a decrease in the neuroprotective effects of leptin [77]. Overall, these studies support a protective role of leptin signaling against cerebrovascular pathologies, but the mechanisms remain unclear.

Leptin has also been demonstrated to have a neuroprotective role against AD pathology and dementia. Preclinical studies have found that leptin can decrease Aβ levels by reducing key enzymes required for Aβ production, increasing Aβ clearance and degradation, and inhibiting the aggregation of Aβ peptides [7882]. Furthermore, exogenous leptin reduces whereas leptin deficiency exacerbates AD pathology and cognitive function in transgenic mouse models of AD [8385]. With notable exceptions [86,87], most epidemiological studies also support the notion that leptin may be protective in dementia, since low plasma leptin levels in late-life are associated with worsening cognitive decline and increased dementia risk in longitudinal studies [88,89]. Furthermore, in cross-sectional studies plasma leptin levels were found to be lower in AD subjects compared to normal controls independent of body weight/adiposity [9092]. Experimental studies also implicated leptin in AD pathology. While there are significant body weight differences among mouse strains [93], several mouse models of AD exhibit low body weight compared to wild-type controls [50,9497]. In one transgenic mouse model overexpressing a mutated form of APP (Tg2576), there was a decrease in body weight and low plasma leptin prior to the development of amyloid pathology and cognitive deficits [50]. These changes in the Tg2576 mice were attributed to Aβ-mediated inhibition of leptin-responsive hypothalamic neurons. As the hypothalamus is affected in AD, these observations suggest that Aβ could directly cause weight loss and low plasma leptin levels by inhibiting neural circuits involved in the regulation of body weight [13,50]. Collectively, these findings open up the possibility that Aβ can be a driver of the weight loss to further decrease plasma leptin and its neuroprotective effects, which would lead to a downward spiral of worsening AD pathology and further weight loss.

Adiponectin: adiposity and systemic metabolism

Adiponectin is a 30kDa adipocyte derived polypeptide that is structurally similar to the complement factor C1q and is comprised of a globular C-terminus domain and a collagenous N-terminus domain with the collagenous domain leading to formation of oligomeric and higher order structures [98,99]. Adiponectin exerts its effects by binding to two related seven transmembrane receptors adipoR1 and adipoR2, which are functionally and topologically distinct from G-protein-coupled receptor [99,100]. Adiponectin circulates in the blood and is relatively abundant representing up to 0.05% of total plasma proteins [98]; however, unlike many adipocyte derived factors, circulating adiponectin levels decrease with increasing adiposity [101]. Low circulating adiponectin levels have been associated with heart failure, coronary artery disease, hepatic steatosis, dyslipidemia and type 2 diabetes, suggesting that adiponectin may have a protective role against obesity-associated disorders [53,99].

Exogenously administering adiponectin has been demonstrated to have multiple effects on body weight and systemic metabolism [53,99]. Adiponectin is an effective insulin sensitizer and can also induce weight loss by acting in the brain to increase energy expenditure [53,99,102]. More recently, a synthetic small molecule adiponectin agonist was reported to significantly improve insulin sensitivity and glucose tolerance leading to increased longevity in a mouse model of obesity, further strengthening the therapeutic potential for adiponectin in treating obesity-associated disorders [103]. Adiponectin-deficient mice exhibit severe diet-induced insulin resistance associated with high levels of tumor necrosis factor-α in adipose tissue and plasma [104]. Furthermore, adiponectin can promote the polarization of tissue macrophages towards an M2 or anti-inflammatory phenotype, suggesting that the insulin sensitizing effects may be mediated by its anti-inflammatory properties [99].

Adiponectin: cerebrovascular disease and dementia

Similar to the systemic obesity-associated disorders, low circulating adiponectin levels have been consistently associated with ischemic cerebrovascular disease [105]. In a case-control study, subjects with ischemic cerebrovascular disease had significantly lower adiponectin levels compared to controls [106]. Another study compared serum adiponectin levels in patients with cerebral infarction with other atherosclerotic disorders and found that basal adiponectin levels were lower in subjects with cerebral infarction compared to healthy controls, but there was no difference between subjects with cerebral infarction and those with other atherosclerotic disorders, such as ischemic heart disease [107]. However, during the acute phase of ischemic stroke, circulating adiponectin levels were temporarily reduced followed by recovery to the low basal levels, suggesting that adiponectin levels can dynamically and acutely change during cerebrovascular insults [107]. Low circulating adiponectin levels have been associated with increased mortality after ischemic stroke and may even help to predict neurological severity and functional outcome [108,109]. In a focal cerebral ischemia model in mice, the overexpression of adiponectin ameliorated the ischemia-induced brain atrophy and improved overall neurological function, effects associated with enhanced angiogenesis [110]. There is also evidence that adiponectin can have protective effects against ischemic insults through endothelial nitric oxide synthase-dependent hemodynamic mechanisms and/or anti-inflammatory effects through the NF-κB pathway [111,112]. Collectively, these studies are consistent with adiponectin having neuroprotective effects against ischemic stroke. Thus, the positive association between obesity and cerebrovascular disease could be explained at least in part by obesity leading to a state of low circulating adiponectin.

The role for adiponectin in age-related dementia is less well established. Exogenous adiponectin was reported to be protective against Aβ-induced neurotoxicity under oxidative stress conditions in a cell model [113]. In epidemiological studies, two independent crosssectional studies found increased plasma and/or CSF adiponectin levels in AD subjects compared to normal controls [91,114], which correlated with worsening cognitive impairment in one of the studies [91]. In addition, a prospective study as part of the Dementia-free Framingham Study found that increased plasma adiponectin levels were an independent risk factor for developing all-cause dementia and AD in elderly women [115]. The association of increased plasma adiponectin levels with dementia found in these studies may be initially surprising since low adiponectin levels are often found in pathological states most commonly seen with obesity-associated disorders. However, these findings are in congruence if one considers that these studies were conducted in late-life with AD, where weight loss may be present (see above), thus leading to higher circulating adiponectin levels. An additional question that would need to be addressed is: if adiponectin generally has protective properties why would high circulating adiponectin levels not improve or decrease the dementia risk? One possibility is that the high circulating adiponectin levels leads to subsequent resistance to adiponectin in a similar fashion to insulin resistance and leptin resistance [116,117]. While showing an association between high plasma adiponectin and dementia, these findings are still controversial. For example, two additional cross-sectional studies found no significant differences in plasma adiponectin levels [90,118], while other studies have found significantly lower circulating adiponectin levels in mild cognitive impairment or AD subjects compared to controls [35,119]. Therefore, the relationship between adiponectin and dementia has not been completely elucidated and additional studies are required to clarify these discrepancies.

Additional adipocyte-related factors

In addition to leptin and adiponectin, there are several other adipocyte-derived factors that could have an impact on age-related dementia such as plasminogen activator inhibitor 1 (PAI-1) and retinol binding protein 4 (RBP4) [120]. Since obesity can be considered a state of inflammation both in brain and in adipose tissue, neuroinflammatory factors associated with obesity could also play a significant role in the development of dementia [121]. In addition, more recently, the gut microbiota transferred from mice on a high-fat diet was found to induce neurobehavioral changes in mice that were on a normal diet, suggesting that changes in the gut microbiome could play a significant role in the cognitive deficits associated with obesity [122]. However, the mediators of this effect remain to be established and it is unclear whether the effects attributed to the gut microbiota are independent of adipocyte-derived hormones such as leptin and adiponectin.

Role of adiposity in age-related dementia: a model reconciling midlife obesity with late-life weight loss

The previous sections have summarized recent findings indicating that adiposity has a complex and significant interaction with the age-related dementia. Midlife obesity seems to contribute and increase the risk for developing dementia, while late-life weight loss portends impending dementia. We propose the following model for how these changes in body weight/adiposity can contribute to age-related dementia (Figure). During midlife, obesity would lead to increased plasma leptin and subsequently leptin resistance, while plasma adiponectin levels will decrease. The net effect of the obesity related leptin resistance and low plasma adiponectin levels would be an increased risk of cerebrovascular damage, decreased resistance to AD pathology, and worsening systemic metabolic deficits, such as insulin resistance, which may independently worsen the cognitive decline [9]. During late-life, AD pathology may cause the weight loss by potentially inhibiting hypothalamic circuits involved in regulating body weight [50]. The weight loss in AD would lead to low plasma leptin, reduced leptin signaling, and high plasma adiponectin, resulting in adiponectin resistance. The net effect of reduced leptin signaling and adiponectin resistance would be similar to the midlife obesity changes, leading to increased cerebrovascular risk, decreased protection against AD pathology and worsening systemic metabolic deficits.

Figure 1
Potential role of adiposity in age-related dementia

This model raises several important questions that need to be addressed. First of all, the high plasma leptin seen in midlife obesity and the high plasma adiponectin seen with AD are presumed to lead to leptin and adiponectin resistance respectively. While there is some evidence to suggest that leptin resistance due to obesity can contribute to worsening AD pathology and cognitive function [30], studies investigating adiponectin resistance in dementia are lacking. In fact, it has not been conclusively established if adiponectin has protective effects against dementia and AD pathology, much less if central adiponectin resistance occurs with age-related dementias. Therefore, careful studies investigating the role of adiponectin in AD are clearly needed. Furthermore, while the focus has been exclusively on leptin and adiponectin, as mentioned above there are other adipose-derived factor that may also be involved. Therefore, a systematic analysis of adipocyte function and adipocyte-derived factors associated with age-related dementias could potentially yield important new candidates. Importantly, due to the inherent metabolic differences between mice and men, findings in mouse models will need to be validated in human studies.

Investigating the effects of body weight and adiposity on age-related dementias also opens the possibility of developing new diagnostic tools and identifying novel therapeutic targets. Both leptin and adiponectin are potential new biomarker candidates for AD. As weight loss often precedes the cognitive symptoms in AD [40], identifying changes in adipocyte-derived factors either in isolation or as an adjunct to other biomarkers may further enhance the diagnosis of AD and related dementias. This could enable earlier diagnosis of the dementia leading to an increased window of opportunity to treat the disease. Additionally, assessing adiposity and adipocyte-derived factors could prove to be useful in therapeutic trials particularly in presymptomatic subjects without cognitive impairment, since it could provide additional information regarding the effectiveness of the drug early in the course of the trial.

Leptin and adiponectin remain active areas of pharmaceutical research, and both have the potential to be used as a therapeutic agent against age-related dementia. Preclinical studies in animal models of AD have demonstrated that leptin treatment can improve both AD pathology and cognitive function [83,84]. Therefore, leptin and its signaling pathways are attractive drug targets against dementia. Furthermore, since leptin treatment is most efficacious against conditions associated with low plasma leptin as opposed to conditions associated with leptin resistance [68], dementia patients who are losing body weight and have low plasma leptin levels might be good candidates for leptin treatment. Due to the paucity of preclinical studies on the effects of adiponectin in AD much less is known about the potential therapeutic benefit of adiponectin, but the recent development of adiponectin receptor agonists is likely to facilitate future drug development based on the adiponectin pathways [103].


We have briefly examined the accumulating evidence supporting the strong relationship between body weight/adiposity and age-related dementia. We highlighted two major adipocyte-derived hormones, leptin and adiponectin, as examples of how changes in adiposity can affect both cerebrovascular and AD pathology to contribute to age-related dementias. Furthermore, we proposed a model where midlife changes in body weight/adiposity leads to alterations in adipocyte-derived hormones to make the brain more susceptible to dementia, whereas late-life changes are one of the earliest signs of impending dementia and may contribute to the overall disease process. While significant advances have been made particularly in identifying the association between body weight/adiposity and dementia, our understanding of this interaction on a molecular and cellular level is still in its infancy leaving significant challenges as well as opportunities for the development of new diagnostic tools and novel drug targets against age-related dementias.


  • Both vascular and Alzheimer’s pathology contribute to age-related dementia.
  • Midlife obesity may increase susceptibility to dementia and Alzheimer’s disease (AD).
  • Late-life weight loss is an early manifestation of AD.
  • Adipocyte hormones leptin and adiponectin affect cerebrovascular and AD pathology.
  • Alterations of leptin and adiponectin may contribute to age-related dementia.


The authors gratefully acknowledge research support from the BrightFocus Foundation (MI), and NS37853 (CI). MI is the recipient of a Paul B. Beeson Award from the National Institute on Aging, the American Federation for Aging Research, The John A. Hartford Foundation and The Atlantic Philanthropies under award K08AG051179. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.




1. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014;88:640–651. [PMC free article] [PubMed]
2. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and “wingmen,” Nature Neuroscience. 2015;18:800–806. [PMC free article] [PubMed]
3. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844–866. [PMC free article] [PubMed]
4. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease--lessons from pathology. BMC Med. 2014;12:206. [PMC free article] [PubMed]
5. Chui HC, Ramirez-Gomez L. Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther. 2015;7:21. [PMC free article] [PubMed]
6. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672–2713. [PMC free article] [PubMed]
7. Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003–2013: a decade of body mass index, Alzheimer's disease, and dementia. Journal of Alzheimer's Disease : JAD. 2015;43:739–755. [PubMed]
8. Iadecola C. Hypertension and dementia. Hypertension. 2014;64:3–5. [PMC free article] [PubMed]
9. Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp. Mol. Med. 2015;47:e149. [PMC free article] [PubMed]
10. Prospective Studies Collaboration. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–1096. [PMC free article] [PubMed]
11. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21:1443–1455. [PubMed]
12. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 2015;116:991–1006. [PMC free article] [PubMed]
13. Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target. Cell Metab. 2015 [PMC free article] [PubMed]
14. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37. [PMC free article] [PubMed]
15. Zea-Sevilla MA, Fernández-Blázquez MA, Calero M, Bermejo-Velasco P, Rábano A. Combined Alzheimer's disease and cerebrovascular staging explains advanced dementia cognition. Alzheimers Dement. 2015 [PubMed]
16. Gaddey HL, Holder K. Unintentional weight loss in older adults. Am Fam Physician. 2014;89:718–722. [PubMed]
17. Schaap LA, Koster A, Visser M. Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. Epidemiol Rev. 2013;35:51–65. [PubMed]
18. Mott JW, Wang J, Thornton JC, Allison DB, Heymsfield SB, Richard J, Pierson N. Relation between body fat and age in 4 ethnic groups. Am. J. Clin. Nutr. 1999;69:1007–1013. [PubMed]
19. Inzitari M, Doets E, Bartali B, Benetou V, Di Bari M, Visser M, Volpato S, Gambassi G, Topinkova E, De Groot L, Salva A. International Association Of Gerontology And Geriatrics (IAGG) Task Force For Nutrition In The Elderly, Nutrition in the age-related disablement process. J Nutr Health Aging. 2011:599–604. [PubMed]
20. Perry HM, Morley JE, Horowitz M, Kaiser FE, Miller DK, Wittert G. Body composition and age in African-American and Caucasian women: relationship to plasma leptin levels. Metab. Clin. Exp. 1997;46:1399–1405. [PubMed]
21. Ding J, Kritchevsky SB, Newman AB, Taaffe DR, Nicklas BJ, Visser M, Lee JS, Nevitt M, Tylavsky FA, Rubin SM, Pahor M, Harris TB. Health ABC study, Effects of birth cohort and age on body composition in a sample of community-based elderly. Am. J. Clin. Nutr. 2007;85:405–410. [PubMed]
22. Balaskó M, Soós S, Székely M, Pétervári E. Leptin and aging: Review and questions with particular emphasis on its role in the central regulation of energy balance. J. Chem. Neuroanat. 2014;61–62:248–255. [PubMed]
23. Paschos GK. Circadian clocks, feeding time, and metabolic homeostasis. Front Pharmacol. 2015;6 [PMC free article] [PubMed]
24. Coomans CP, Lucassen EA, Kooijman S, Fifel K, Deboer T, Rensen PCN, Michel S, Meijer JH. Plasticity of circadian clocks and consequences for metabolism. Diabetes Obes Metab. 2015;17:65–75. [PubMed]
25. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology. 2011;76:1568–1574. [PMC free article] [PubMed]
26. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057–1064. [PubMed]
27. Hassing LB, Dahl AK, Thorvaldsson V, Berg S, Gatz M, Pedersen NL, Johansson B. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int J Obes (Lond) 2009;33:893–898. [PMC free article] [PubMed]
28. Morris MC, Tangney CC. Dietary fat composition and dementia risk. Neurobiol. Aging. 2014;35(Suppl 2):S59–S64. [PMC free article] [PubMed]
29. Refolo LM, Malester B, Lafrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000;7:321–331. [PubMed]
30. Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P, Calon F. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging. 2010;31:1516–1531. [PubMed]
31. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Bmj. 2005;330:1360–1360. [PMC free article] [PubMed]
32. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala E-L, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Archives of Neurology. 2005;62:1556–1560. [PubMed]
33. Chiang C-J, Yip P-K, Wu S-C, Lu C-S, Liou C-W, Liu H-C, Liu C-K, Chu C-H, Hwang C-S, Sung S-F, Hsu Y-D, Chen C-C, Liu S-I, Yan S-H, Fong C-S, Chang S-F, You S-L, Chen C-J. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry. 2007;15:762–771. [PubMed]
34. Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, Evans SJW, Pocock SJ. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol. 2015;3:431–436. [PubMed]
35. Kamogawa K, Kohara K, Tabara Y, Uetani E, Nagai T, Yamamoto M, Igase M, Miki T. Abdominal fat, adipose-derived hormones and mild cognitive impairment: the JSHIPP study. Dement Geriatr Cogn Disord. 2010;30:432–439. [PubMed]
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34:939–944. [PubMed]
37. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc. 1996;44:265–272. [PubMed]
38. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46:1223–1227. [PubMed]
39. Power BD, Alfonso H, Flicker L, Hankey GJ, Yeap BB, Almeida OP. Changes in body mass in later life and incident dementia. Int Psychogeriatr. 2013;25:467–478. [PubMed]
40. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Archives of Neurology. 2006;63:1312–1317. [PubMed]
41. Hughes TF, Borenstein AR, Schofield E, Wu Y, Larson EB. Association between late-life body mass index and dementia: The Kame Project. Neurology. 2009;72:1741–1746. [PMC free article] [PubMed]
42. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology. 2005;65:892–897. [PubMed]
43. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc. 1996;44:1147–1152. [PubMed]
44. Stewart R, Masaki K, Xue Q-L, Peila R, Petrovitch H, White LR, Launer LJ. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Archives of Neurology. 2005;62:55–60. [PubMed]
45. Gao S, Nguyen JT, Hendrie HC, Unverzagt FW, Hake A, Smith-Gamble V, Hall K. Accelerated weight loss and incident dementia in an elderly African-American cohort. J Am Geriatr Soc. 2011;59:18–25. [PMC free article] [PubMed]
46. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–292. [PMC free article] [PubMed]
47. Buchman AS, Schneider JA, Wilson RS, Bienias JL, Bennett DA. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology. 2006;67:1949–1954. [PubMed]
48. Vidoni ED, Townley RA, Honea RA, Burns JM. Alzheimer’s Disease Neuroimaging Initiative, Alzheimer disease biomarkers are associated with body mass index. Neurology. 2011;77:1913–1920. [PMC free article] [PubMed]
49. Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H. Alzheimer’s Disease Neuroimaging Initiative, Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol. Aging. 2012;33:1599–1608. [PMC free article] [PubMed]
50. Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. Transgenic Mice Overexpressing Amyloid Precursor Protein Exhibit Early Metabolic Deficits and a Pathologically Low Leptin State Associated with Hypothalamic Dysfunction in Arcuate Neuropeptide Y Neurons. Journal of Neuroscience. 2014;34:9096–9106. [PMC free article] [PubMed]
51. Ishii M, Iadecola C. Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. Cell Metab. 2015 [PMC free article] [PubMed]
52. Friedman JM, Mantzoros CS. 20 years of leptin: From the discovery of the leptin gene to leptin in our therapeutic armamentarium. Metab. Clin. Exp. 2015;64:1–4. [PubMed]
53. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metab. Clin. Exp. 2015;64:131–145. [PubMed]
54. Friedman J. 20 years of leptin: leptin at 20: an overview. J. Endocrinol. 2014;223:T1–T8. [PubMed]
55. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1995;1:1155–1161. [PubMed]
56. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. Journal of Clinical Endocrinology & Metabolism. 1996;81:3419–3423. [PubMed]
57. Ruhl CE, Harris TB, Ding J, Goodpaster BH, Kanaya AM, Kritchevsky SB, Simonsick EM, Tylavsky FA, Everhart JE. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am. J. Clin. Nutr. 2007;85:1121–1126. [PubMed]
58. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am. J. Clin. Nutr. 2001;74:295–301. [PubMed]
59. Allison MB, Myers MG. 20 years of leptin: connecting leptin signaling to biological function. J. Endocrinol. 2014;223:T25–T35. [PMC free article] [PubMed]
60. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov. 2012;11:692–708. [PMC free article] [PubMed]
61. Knights AJ, Funnell AP, Pearson RC, Crossley M, Bell-Anderson KS. Adipokines and insulin action: A sensitive issue. Adipocyte. 2014;3:88–96. [PMC free article] [PubMed]
62. Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, Bassi J, Elmquist JK, Keogh JM, Henning E, Myers MG, Jr, Licinio J, Brown RD, Enriori PJ, O’Rahilly S, Sternson SM, Grove KL, Spanswick DC, Farooqi IS, Cowley MA. Leptin Mediates the Increase in Blood Pressure Associated with Obesity. Cell. 2014;159:1404–1416. [PMC free article] [PubMed]
63. Brown RJ, Meehan CA, Gorden P. Leptin Does Not Mediate Hypertension Associated With Human Obesity. Cell. 2015;162:465–466. [PubMed]
64. Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013;18:29–42. [PubMed]
65. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879–884. [PubMed]
66. Myers MG, Heymsfield SB, Haft C, Kahn BB, Laughlin M, Leibel RL, Tschöp MH, Yanovski JA. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 2012;15:150–156. [PMC free article] [PubMed]
67. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Jama. 1999;282:1568–1575. [PubMed]
68. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metab. Clin. Exp. 2015;64:146–156. [PubMed]
69. Zhang F, Wang S, Signore AP, Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke. 2007;38:2329–2336. [PubMed]
70. Zhang F, Chen J. Leptin protects hippocampal CA1 neurons against ischemic injury. J. Neurochem. 2008;107:578–587. [PMC free article] [PubMed]
71. Busch H-J, Schirmer SH, Jost M, van Stijn S, Peters SLM, Piek JJ, Bode C, Buschmann IR, Mies G. Leptin augments cerebral hemodynamic reserve after three-vessel occlusion: distinct effects on cerebrovascular tone and proliferation in a nonlethal model of hypoperfused rat brain. J. Cereb. Blood Flow Metab. 2011;31:1085–1092. [PMC free article] [PubMed]
72. Terao S, Yilmaz G, Stokes KY, Ishikawa M, Kawase T, Granger DN. Inflammatory and injury responses to ischemic stroke in obese mice. Stroke. 2008;39:943–950. [PubMed]
73. Guo Z, Jiang H, Xu X, Duan W, Mattson MP. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J. Biol. Chem. 2008;283:1754–1763. [PubMed]
74. Söderberg S, Stegmayr B, Ahlbeck-Glader C, Slunga-Birgander L, Ahrén B, Olsson T. High leptin levels are associated with stroke. Cerebrovasc. Dis. 2003;15:63–69. [PubMed]
75. Jaleel A, Aqil S, Jaleel S, Jaleel F. Adipocytokines in Subjects with and without Ischemic Cerebrovascular Disease. Acta Neurol Belg. 2010;110:234–238. [PubMed]
76. Jalil A, Amir S, Majeed R, Jalil F. Circulating leptin levels in elderly subjects with and without cerebrovasular disease. J Coll Physicians Surg Pak. 2010;20:350–351. [PubMed]
77. Davis C, Mudd J, Hawkins M. Neuroprotective effects of leptin in the context of obesity and metabolic disorders. Neurobiol. Dis. 2014;72(Pt A):61–71. [PubMed]
78. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. The FASEB Journal. 2004;18:1870–1878. [PubMed]
79. Marwarha G, Raza S, Meiers C, Ghribi O. Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim. Biophys. Acta. 2014;1842:1587–1595. [PMC free article] [PubMed]
80. Yamamoto N, Tanida M, Kasahara R, Sobue K, Suzuki K. Leptin inhibits amyloid β-protein fibrillogenesis by decreasing GM1 gangliosides on the neuronal cell surface through PI3K/Akt/mTOR pathway. J. Neurochem. 2014;131:323–332. [PubMed]
81. Greco SJ, Hamzelou A, Johnston JM, Smith MA, Ashford JW, Tezapsidis N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons. Biochem. Biophys. Res. Commun. 2011;414:170–174. [PMC free article] [PubMed]
82. Marwarha G, Dasari B, Prasanthi JRP, Schommer J, Ghribi O. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. Journal of Alzheimer's Disease : JAD. 2010;19:1007–1019. [PMC free article] [PubMed]
83. Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N, Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : JAD. 2010;19:1155–1167. [PMC free article] [PubMed]
84. Pérez-González R, Alvira-Botero MX, Robayo O, Antequera D, Garzón M, Martín-Moreno AM, Brera B, de Ceballos ML, Carro E. Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice. Gene Ther. 2014 [PubMed]
85. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U.S.a. 2010;107:7036–7041. [PubMed]
86. Oania R, McEvoy LK. Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. Age and Ageing. 2015;44:53–58. [PMC free article] [PubMed]
87. Teunissen CE, van der Flier WM, Scheltens P, Duits A, Wijnstok N, Nijpels G, Dekker JM, Blankenstein RMA, Heijboer AC. Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. Journal of Alzheimer's Disease : JAD. 2015;44:809–813. [PubMed]
88. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K. Health ABC study, Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol. Aging. 2009;30:1483–1489. [PMC free article] [PubMed]
89. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S. Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging. Jama. 2009;302:2565–2572. [PMC free article] [PubMed]
90. Bigalke B, Schreitmüller B, Sopova K, Paul A, Stransky E, Gawaz M, Stellos K, Laske C. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS ONE. 2011;6:e20286. [PMC free article] [PubMed]
91. Khemka VK, Bagchi D, Bandyopadhyay K, Bir A, Chattopadhyay M, Biswas A, Basu D, Chakrabarti S. Altered Serum Levels of Adipokines and Insulin in Probable Alzheimer's Disease. Journal of Alzheimer's Disease : JAD. 2014;41:525–533. [PubMed]
92. Baranowska-Bik A, Bik W, Styczynska M, Chodakowska-Zebrowska M, Barcikowska M, Wolinska-Witort E, Kalisz M, Martynska L, Baranowska B. Plasma leptin levels and free leptin index in women with Alzheimer's disease. Neuropeptides. 2015;52:73–78. [PubMed]
93. Reed DR, Bachmanov AA, Tordoff MG. Forty mouse strain survey of body composition. Physiol. Behav. 2007;91:593–600. [PMC free article] [PubMed]
94. Vloeberghs E, Van Dam D, Franck F, Serroyen J, Geert M, Staufenbiel M, De Deyn PP. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behav. Neurosci. 2008;122:491–497. [PubMed]
95. Wirths O, Breyhan H, Schäfer S, Roth C, Bayer TA. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol. Aging. 2008;29:891–901. [PubMed]
96. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav. Brain Res. 2007;178:18–28. [PubMed]
97. Li G, Jack CR, Yang X-F, Yang ES. Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI study. Biofactors. 2008;32:169–178. [PubMed]
98. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995;270:26746–26749. [PubMed]
99. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55:2319–2326. [PubMed]
100. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–769. [PubMed]
101. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999;257:79–83. [PubMed]
102. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. Adiponectin acts in the brain to decrease body weight. Nat. Med. 2004;10:524–529. [PubMed]
103. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K-I, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503:493–499. [PubMed]
104. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002;8:731–737. [PubMed]
105. Yang Y, Hu W, Jiang S, Wang B, Li Y, Fan C, Di S, Ma Z, Lau WB, Qu Y. The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases. Biochim. Biophys. Acta. 2015;1852:1887–1894. [PubMed]
106. Chen M-P, Tsai JC-R, Chung F-M, Yang S-S, Hsing L-L, Shin S-J, Lee Y-J. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 2005;25:821–826. [PubMed]
107. Sasaki M, Kawano T, Saito T, Yuzawa M, Saito T, Ikoma A, Tamemoto H, Kawakami M, Ishikawa S-E. Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders. Am. J. Med. Sci. 2007;333:140–144. [PubMed]
108. Kuwashiro T, Ago T, Kamouchi M, Matsuo R, Hata J, Kuroda J, Fukuda K, Sugimori H, Fukuhara M, Awano H, Isomura T, Suzuki K, Yasaka M, Okada Y, Kiyohara Y, Kitazono T. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS) Metab. Clin. Exp. 2014;63:1093–1103. [PubMed]
109. Efstathiou SP, Tsioulos DI, Tsiakou AG, Gratsias YE, Pefanis AV, Mountokalakis TD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke. 2005;36:1915–1919. [PubMed]
110. Shen L, Miao J, Yuan F, Zhao Y, Tang Y, Wang Y, Zhao Y, Yang G-Y. Overexpression of adiponectin promotes focal angiogenesis in the mouse brain following middle cerebral artery occlusion. Gene Ther. 2013;20:93–101. [PubMed]
111. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz MA, Ouchi N. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation. 2008;117:216–223. [PubMed]
112. Chen B, Liao W-Q, Xu N, Xu H, Wen J-Y, Yu C-A, Liu X-Y, Li C-L, Zhao S-M, Campbell W. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res. 2009;1273:129–137. [PubMed]
113. Chan K-H, Lam KS-L, Cheng O-Y, Kwan JS-C, Ho PW-L, Cheng KK-Y, Chung SK, Ho JW-M, Guo VY, Xu A. Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PLoS ONE. 2012;7:e52354. [PMC free article] [PubMed]
114. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K, Arai H. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol. 2011;18:1006–1009. [PubMed]
115. van Himbergen TM, Beiser AS, Ai M, Seshadri S, Otokozawa S, Au R, Thongtang N, Wolf PA, Schaefer EJ. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. Archives of Neurology. 2012;69:594–600. [PMC free article] [PubMed]
116. Lin HV, Kim J-Y, Pocai A, Rossetti L, Shapiro L, Scherer PE, Accili D. Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes. 2007;56:1969–1976. [PubMed]
117. Li R, Lau WB, Ma XL. Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol. Sin. 2010;31:1258–1266. [PMC free article] [PubMed]
118. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer's disease. Journal of Alzheimer's Disease : JAD. 2012;29:151–157. [PMC free article] [PubMed]
119. Teixeira AL, Diniz BS, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, Forlenza OV. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromolecular Med. 2013;15:115–121. [PubMed]
120. Kiliaan AJ, Arnoldussen IAC, Gustafson DR. Adipokines: a link between obesity and dementia? The Lancet Neurology. 2014;13:913–923. [PMC free article] [PubMed]
121. Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and neuroinflammation. Neuropharmacology. 2015;96:124–134. [PubMed]
122. Bruce-Keller AJ, Salbaum JM, Luo M, Blanchard E, Taylor CM, Welsh DA, Berthoud H-R. Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. Biol. Psychiatry. 2015;77:607–615. [PMC free article] [PubMed]
123. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, Luchsinger JA. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Archives of Neurology. 2009;66:336–342. [PMC free article] [PubMed]
124. Ravona-Springer R, Schnaider-Beeri M, Goldbourt U. Body weight variability in midlife and risk for dementia in old age. Neurology. 2013;80:1677–1683. [PMC free article] [PubMed]
125. Tolppanen A-M, Ngandu T, Kåreholt I, Laatikainen T, Rusanen M, Soininen H, Kivipelto M. Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. Journal of Alzheimer's Disease : JAD. 2014;38:201–209. [PubMed]